Keyword: Regeneron Pharmaceuticals
After launching at about the same price—$14,000-plus—Praluent and Repatha again stand on par. But this time, it’s less than half the original sticker.
Regeneron's CEO calls Libtayo “the engine that could.” And Wednesday, those wondering, “could what?” got a glimpse at what the drug has done so far.
It wasn't just deals folks were buzzing about in meeting rooms, restaurants and hotel lobbies, as our top FierceBiotech and FiercePharma stories show.
Investors had been worried that growth for Regeneron’s Eylea was slowing down, but Monday the company batted away those fears.
Amgen failed to keep Repatha rival Praluent off the market with a patent challenge, but it's hoping more price cuts will help it grab market share.
The eye drug star has nabbed an FDA nod as a 12-week formulation in wet AMD and is expected to get into diabetic retinopathy next May.
While the administration wants to attack "global freeloading" and reduce U.S. prices, some companies are set to feel the pain more than others.
Roche and Novartis are working hard on AMD drugs they hope can capture significant market share. Analysts, though, remain unconvinced.
Regeneron has received a complete response letter tied to manufacturing of a syringe as it shoots for another indication for blockbuster Eylea.
It's common for drugmakers to offer behind-the-scenes rebates to win coverage for their drugs. But Amgen's big retail price cut is a rare move.